Literature DB >> 23850083

Classification of hospital pathways in the management of cancer: application to lung cancer in the region of burgundy.

G Nuemi1, F Afonso, A Roussot, L Billard, J Cottenet, E Combier, E Diday, C Quantin.   

Abstract

CONTEXT: The evaluation of national cancer plans is an important aspect of their implementation. For this evaluation, the principal actors in the field (doctors, nurses, etc.) as well as decision-makers must have access to information that is reliable, synthetic and easy to interpret, and which reflects the implementation process in the field. We propose here a methodology to make this type of information available in the context of reducing inequalities with regard to access to healthcare for patients with lung cancer in the region of Burgundy.
METHODS: We used the national medico-administrative DRG-type database, which gathers together all hospital stays. By using this database, it was possible to identify and reconstruct the care management history of these patients. That is, by linking together all attended hospitals, sorted chronologically. Eligible patients were at least 18 years old, whatever the gender and had undergone surgery for their lung cancer. They had to be residents of Burgundy at the time of the first operation between 2006 and 2008. Patient's pathway was defined as the sequence of all attended hospitals (hospital stays) during the year of follow up linked together using an anonymised patient identifier. We then constructed a pathway typology of pathway using an unsupervised clustering method, and conducted a spatial analysis of this typology.
RESULTS: Between 2006 and 2008, we selected 495 patients in the 4 administrative departments of the Burgundy region. They accounted for a total of 3821 stays during the year of follow-up. There were 393 men (79%) and the mean age was 64 (95% confidence interval: 63-65) years. We reconstructed 94 pathways (about five per patient). Here, neighbourhood's cares accounted for 41% of them, while 44% included a surgical intervention outside the region of Burgundy. We constructed a pathway typology with five classes. Spatial analysis showed that the vast majority of initial surgeries took place in the major regional centres.
CONCLUSION: The construction of a pathway typology leads to better understanding of the reasoning that lies behind the movements of patients. It opens the way for analysis of the collaboration between the different healthcares establishments attended, which should bring to light associations that need to be developed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clustering; Epidemiology; Hospital information systems; Lung neoplasm; Management care pathways; Medical record linkage

Mesh:

Year:  2013        PMID: 23850083     DOI: 10.1016/j.canep.2013.06.007

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307).

Authors:  Gillles Nuemi; Hervé Devilliers; Karine Le Malicot; Rosine Guimbaud; Côme Lepage; Catherine Quantin
Journal:  Health Qual Life Outcomes       Date:  2015-09-22       Impact factor: 3.186

2.  Spread of hospital-acquired infections: A comparison of healthcare networks.

Authors:  Narimane Nekkab; Pascal Astagneau; Laura Temime; Pascal Crépey
Journal:  PLoS Comput Biol       Date:  2017-08-24       Impact factor: 4.475

3.  Depression and obesity, data from a national administrative database study: Geographic evidence for an epidemiological overlap.

Authors:  Jean-Christophe Chauvet-Gelinier; Adrien Roussot; Jonathan Cottenet; Marie-Claude Brindisi; Jean-Michel Petit; Bernard Bonin; Bruno Vergès; Catherine Quantin
Journal:  PLoS One       Date:  2019-01-08       Impact factor: 3.240

4.  Clinical and operational insights from data-driven care pathway mapping: a systematic review.

Authors:  Matthew Manktelow; Aleeha Iftikhar; Magda Bucholc; Michael McCann; Maurice O'Kane
Journal:  BMC Med Inform Decis Mak       Date:  2022-02-17       Impact factor: 2.796

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.